Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8WZ82
UPID:
OVCA2_HUMAN
Alternative names:
Ovarian cancer-associated gene 2 protein
Alternative UPACC:
Q8WZ82; Q86XN3; Q8IW87; Q9UCX9
Background:
Esterase OVCA2, also known as Ovarian cancer-associated gene 2 protein, is a notable enzyme in the realm of biochemistry. Its alternative name hints at a potential link to ovarian cancer, although its specific functions and mechanisms of action are yet to be fully elucidated. The protein's unique esterase activity suggests it plays a crucial role in various biological processes, including the breakdown of ester bonds.
Therapeutic significance:
Understanding the role of Esterase OVCA2 could open doors to potential therapeutic strategies. Its association with ovarian cancer, as suggested by its alternative name, makes it a promising target for drug discovery efforts aimed at developing novel treatments for this and potentially other related diseases.